SCHEMBL2132230

SCHEMBL2132230

NC(CO)C(=O)NC(Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 2/20 0.36
▸ CPB2 Q96IY4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30559586 1.00 MME (0.36) MMECPB2
SCHEMBL2132240 1.00 MME (0.36) MMECPB2
SCHEMBL30272502 0.97 MME (0.34) MMECPB2
SCHEMBL29630312 0.97 MME (0.34) MMECPB2
SCHEMBL29630315 0.95 MME (0.36) MME
SCHEMBL29590288 0.95 MME (0.36) MME
SCHEMBL29777856 0.94 MME (0.39) MMECPB2
SCHEMBL29461527 0.93 MME (0.39) MME
SCHEMBL30781267 0.93 BACE1 (0.34) —
SCHEMBL29374958 0.93 MME (0.36) MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-60248618-A — — None — — JP disclosed
US-20260009071-A1 METHODS OF IN-SOLUTION POSITIONAL CO-BARCODING FOR SEQUENCING LONG DNA MOLECULES MGI TECH CO LTD (CN) 2026-01-08 — — US disclosed
EP-4562143-A1 METHODS OF IN-SOLUTION POSITIONAL CO-BARCODING FOR SEQUENCING LONG DNA MOLECULES MGI Tech Co., Ltd. (CN) 2025-06-04 — — EP disclosed
US-20240240174-A1 NICK-LIGATE STLFR MGI TECH CO., LTD. (CN) 2024-07-18 — — US disclosed
EP-4373959-A1 NICK-LIGATE STLFR MGI Tech Co., Ltd. (CN) 2024-05-29 — — EP disclosed
CN-118019856-A Notch-connection STLFR 深圳华大智造科技股份有限公司 2024-05-10 — — CN disclosed
US-20240043924-A1 DETERMINING LONG DNA SEQUENCE USING SHORT MPS READS MGI TECH CO., LTD. (CN) 2024-02-08 — — US disclosed
CN-117512081-A Determination of Long DNA sequences Using short MPS reads 深圳华大智造科技股份有限公司 2024-02-06 — — CN disclosed
WO-2024022207-A1 METHODS OF IN-SOLUTION POSITIONAL CO-BARCODING FOR SEQUENCING LONG DNA MOLECULES MGI TECH CO., LTD. (CN) 2024-02-01 — — WO disclosed
WO-2023001262-A1 NICK-LIGATE STLFR MGI TECH CO., LTD. (CN) 2023-01-26 — — WO disclosed
US-20140227345-A1 COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES MARINA BIOTECH, INC. (US) 2014-08-14 — — US disclosed
US-8580297-B2 Components for producing amphoteric liposomes MARINA BIOTECH, INC. (US) 2013-11-12 — — US disclosed
US-20120100205-A1 COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES MARINA BIOTECH, INC. 2012-04-26 — — US disclosed
WO-2011086553-A1 CYCLIC PEPTIDES, COMPOSITIONS COMPRISING THEM AND USES THEREOF AS NUCLEASES OF NUCLEOTIDIC MACROMOLECULES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2011-07-21 — — WO disclosed
US-20090047272-A1 Compositions with Modified Nucleases Targeted to Viral Nucleic Acids and Methods of Use for Prevention and Treatment of Viral Diseases NANONASE, INC. 2009-02-19 — — US disclosed
EP-1734991-A2 COMPOSITIONS WITH MODIFIED NUCLEASES TARGETED TO VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR PREVENTION AND TREATMENT OF VIRAL DISEASES Avirid, Inc. (US) 2006-12-27 — — EP disclosed
WO-2005115444-A2 COMPOSITIONS WITH MODIFIED NUCLEASES TARGETED TO VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR PREVENTION AND TREATMENT OF VIRAL DISEASES AVIRID, INC. (US) 2005-12-08 — — WO disclosed
US-20050164963-A1 Components for producing amphoteric liposomes CAVALRY FUND I LP 2005-07-28 — — US disclosed
WO-2002040631-A2 DIPEPTIDE SERYL-HISTIDINE AND RELATED OLIGOPEPTIDES CLEAVE DNA, PROTEIN, AND A CARBOXYL ESTER OHIO UNIVERSITY (US) 2002-05-23 — — WO disclosed
JP-S60248618-A DIPEPTIDE-CONTAINING REMEDY FOR ULCER NIPPON ZOKI PHARMACEUT CO LTD 1985-12-09 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260009071-A1 METHODS OF IN-SOLUTION POSITIONAL CO-BARCODING FOR SEQUENCING LONG DNA MOLECULES RNGTT, POLM, NUDT21 MME 2812/4885CPB2 2727/4885
US-20140227345-A1 COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES PHOSPHO1, SGMS1, CHMP4B MME 1442/4885CPB2 2298/4885
US-20050164963-A1 Components for producing amphoteric liposomes PHOSPHO1, SGMS1, CHMP4B MME 1442/4885CPB2 2298/4885
US-20120100205-A1 COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES PHOSPHO1, SGMS1, CHMP4B MME 1442/4885CPB2 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback